American Vanguard Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVD research report →
Range $14 – $20
Price Chart
About the company
American Vanguard Corporation, through its various subsidiaries, develops, manufactures, and markets a diverse portfolio of specialized chemicals for agricultural, commercial, and consumer applications across the United States and internationally. The company formulates and produces a comprehensive range of chemicals, including pest control agents like insecticides, fungicides, herbicides, and molluscicides, as well as solutions for soil health, plant nutrition, growth regulation, and soil fumigation. These offerings are available in liquid, powder, and granular forms, serving purposes in crop cultivation, turf and ornamental plant management, and human and animal health protection.
- CEO
- Douglas A. Kaye
- IPO
- 1987
- Employees
- 739
- HQ
- Newport Beach, CA, US
Get TickerSpark's AI analysis on AVD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $20.10M
- P/E
- -0.37
- Fwd P/E
- 1.79
- PEG
- -0.02
- P/S
- 0.04
- P/B
- 0.13
- EV/EBITDA
- -19.70
- Div Yield
- 0.00%
- Gross Margin
- 28.43%
- Op Margin
- 0.46%
- Net Margin
- -11.99%
- ROE
- -32.98%
- ROIC
- 0.51%
Latest fiscal year · YoY change
- Revenue
- $515.11M-5.9%
- Gross Profit
- $147.56M+22.6%
- Op Income
- $13.77M
- Net Income
- $-49,882,000+60.5%
- EPS
- $-1.75+61.1%
- OCF Growth
- -640.2%
- FCF Growth
- -571.3%
- 52W High
- $5.55
- 52W Low
- $0.65
- 50D MA
- $1.39
- 200D MA
- $2.59
- Beta
- 1.56
- RSI (14)
- 22
- Avg Volume
- 403.95K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
American Vanguard missed on sales and profitability in Q3, but management pointed to cost actions, cash generation, and new product/portfolio additions as the setup for a stronger Q4 and longer-term growth.· November 9, 2026
- Q3 net sales were $108 million, down 9% year over year, and adjusted EBITDA was essentially breakeven, down $8.3 million from last year.
- Gross margin fell to 24.2% from 28.7% as freight costs, higher raw materials, and weaker fixed-cost leverage outweighed manufacturing improvements.
- Full-year 2026 guidance was cut to $500 million-$530 million of revenue and $36 million-$40 million of adjusted EBITDA.
- Cash improved to $84 million, up $40 million sequentially, while net debt declined to about $183.8 million and leverage was 6.5x versus a 6.7x covenant max.
- Management said Q4 should improve, with projected sales of about $166 million and adjusted EBITDA of $21 million, helped by higher volumes, new products, and cost savings.
Q3 2026 net sales were $108 million, down 9% from $119 million a year ago; adjusted EBITDA was approximately breakeven, down $8.3 million year over year. Gross margin was 24.2% versus 28.7% in Q3 2025; for the first 9 months, sales were $349 million, down 4% from $364 million, and gross margin was flat year over year. Management lowered full-year 2026 guidance to revenue of $500 million-$530 million and adjusted EBITDA of $36 million-$40 million, from prior guidance of $530 million-$550 million and $44 million-$48 million, respectively. For Q4 2026, the company expects net sales of about $166 million and adjusted EBITDA of $21 million. Cash at quarter-end was $84 million, net debt was about $183.8 million, and gross leverage was 6.5x versus a 6.7x covenant maximum.
Dak Kaye framed the quarter as evidence that the company’s cost actions and commercial changes are starting to work, even though the market backdrop remains difficult. He emphasized stronger U.S. execution, completed footprint actions, and a new product pipeline as the main levers for growth over the next several years. His tone was cautious but constructive: he repeatedly noted that external conditions are unfavorable, while saying the company is focused on controlling what it can control and improving execution.
Matt Horwath highlighted that Q3 sales were $108 million versus $119 million last year, with gross margin at 24.2% versus 28.7% due to freight costs, raw materials, and lower fixed-cost leverage. He said non-GAAP operating expense was $27.8 million, down $800,000 year over year, and transformation costs were $1.7 million in the quarter. On the balance sheet, cash ended at $84 million, up $40 million sequentially, inventory was down $4.9 million year over year, debt was $267.7 million, net debt was about $183.8 million, and leverage was 6.5x. He also said fourth-quarter prepayment and early pay collections are expected to be $45 million, and that net working capital should be a positive liquidity contributor in Q4.
The main question focused on the $5 million acquisition and related revenue contribution. Management said the deal actually has a total value of $9.5 million including a deferred payment, adds four branded U.S. specialty/niche crop products plus technical registrations, and is part of a broader $15 million-$20 million annualized revenue contribution when combined with the Sipcam distribution agreement. When asked whether those revenues were future or current, management said they are being realized now and are included in the Q4 2026 outlook. On guidance visibility, management said the fourth quarter is not fully ‘baked’ because agriculture is still a sell-through business and execution remains dependent on commercial performance.
Management believes the company is starting to see the benefit of footprint rationalization, lower operating expenses, and tighter working capital management. They also pointed to a growing new product pipeline, including Duro LQ in the U.S. and recent brand/distribution additions, as support for growth into 2028 and beyond. They reiterated a goal of more than $600 million in annualized sales by the back half of 2028 and eventually getting EBITDA margin into double digits.
The call repeatedly stressed weak global agriculture markets, El Nino-related disruption, and lean inventory buying by customers, especially internationally. Freight costs, especially diesel, are still hurting gross margin and management said they have not been able to raise prices fast enough to fully offset inflation. Management also cut full-year guidance, and the Q4 recovery still depends on better execution in a market they said will likely remain challenging.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.1%
- Shares Outstanding
- 29.55M
- Float Shares
- 28.41M
of shares held by institutions
108 13F filers
Buy/sell ratio 2.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Wellington Management Group Llp | 1.72M | ▲ 68.11K |
| Vanguard Group Inc | 1.55M | ▲ 7.20K |
| Vanguard Capital Management LLC | 1.12M | ▼ 27.70K |
| Blackrock, Inc. | 1.01M | ▲ 76.63K |
| Two Sigma Investments, LP | 732.82K | ▼ 13.37K |
| Potomac Capital Management, Inc. | 583.67K | ▲ 224.90K |
| Cruiser Capital Advisors, LLC | 571.78K | 0 |
| Dimensional Fund Advisors LP | 559.46K | ▼ 215.13K |
| Rbf Capital, LLC | 540.81K | ▲ 122.22K |
| D. E. Shaw & Co., Inc. | 530.01K | ▲ 26 |
| Castleknight Management LP | 504.33K | 0 |
| Marshall Wace, Llp | 464.15K | ▲ 390.95K |
Held by 47 ETFs
Biggest fund positions in AVD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Horwath Matthew | other | 150,000 |
| Oct 1, 26 | Horwath Matthew | other | 100,000 |
| Oct 1, 26 | Horwath Matthew | other | 0 |
| Aug 18, 26 | ROSENBLOOM KEITH M | sell | 556,580 |
| Aug 17, 26 | Macicek Steven D | buy | 19,000 |
| Jul 10, 26 | Kaye Douglas | other | 6,527 |
| Jun 4, 26 | ROSENBLOOM KEITH M | other | 31,872 |
| Jun 4, 26 | Johnson David` T. | other | 20,000 |
| Jun 4, 26 | Kaye Douglas | other | 50,000 |
| Jun 3, 26 | Kaye Douglas | buy | 5,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AVD coverage
Recent articles, reports, and earnings notes.
No research on AVD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVD report →AVD Shares Fall 6.4% After Q3 Loss Widens Y/Y, Guidance Lowered
zacks.com · Nov 13
American Vanguard: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 10
American Vanguard Corporation (AVD) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity
seekingalpha.com · Oct 30
Zacks Initiates Coverage of AVD With Neutral Recommendation
zacks.com · Oct 27
American Vanguard Corporation (AVD) Announces CFO Transition
accessnewswire.com · Oct 1
American Vanguard Announces Acquisition of U.S. Crop-Protection Products from Syngenta
accessnewswire.com · Sep 29
American Vanguard Corporation (AVD) Announces Executive Appointment of Mark Helt as U.S. Crop President
accessnewswire.com · Aug 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.